BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16945990)

  • 21. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.
    Weis KE; Ekena K; Thomas JA; Lazennec G; Katzenellenbogen BS
    Mol Endocrinol; 1996 Nov; 10(11):1388-98. PubMed ID: 8923465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
    Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB
    Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
    Staka CM; Nicholson RI; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S85-97. PubMed ID: 16113102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo.
    Faridi J; Wang L; Endemann G; Roth RA
    Clin Cancer Res; 2003 Aug; 9(8):2933-9. PubMed ID: 12912939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells.
    Zhang CC; Krieg S; Shapiro DJ
    Mol Endocrinol; 1999 Apr; 13(4):632-43. PubMed ID: 10194768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
    Pietras RJ; Arboleda J; Reese DM; Wongvipat N; Pegram MD; Ramos L; Gorman CM; Parker MG; Sliwkowski MX; Slamon DJ
    Oncogene; 1995 Jun; 10(12):2435-46. PubMed ID: 7784095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.
    Lazennec G; Ediger TR; Petz LN; Nardulli AM; Katzenellenbogen BS
    Mol Endocrinol; 1997 Aug; 11(9):1375-86. PubMed ID: 9259327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.
    Chen D; Washbrook E; Sarwar N; Bates GJ; Pace PE; Thirunuvakkarasu V; Taylor J; Epstein RJ; Fuller-Pace FV; Egly JM; Coombes RC; Ali S
    Oncogene; 2002 Jul; 21(32):4921-31. PubMed ID: 12118371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells.
    Rai D; Frolova A; Frasor J; Carpenter AE; Katzenellenbogen BS
    Mol Endocrinol; 2005 Jun; 19(6):1606-17. PubMed ID: 15831524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells.
    Singleton DW; Feng Y; Burd CJ; Khan SA
    Endocrinology; 2003 Jan; 144(1):121-8. PubMed ID: 12488337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
    Girault I; Bièche I; Lidereau R
    Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
    Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
    Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.
    Yang X; Yang S; McKimmey C; Liu B; Edgerton SM; Bales W; Archer LT; Thor AD
    Carcinogenesis; 2010 Apr; 31(4):695-702. PubMed ID: 20067990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.